2026 Special PARPi Funding Round – ‘Patient preferences on the use of PARP inhibitors to reduce the risk of cancer’ content
This funding round is now closed
The 2026 Special PARPi Funding Round is for patient preference studies to explore whether PARPi can be used as a chemopreventative treatment for people at high risk of hereditary cancers, as part of a drive toward a future of precision cancer prevention.
This funding opportunity follows the publication of a joint position statement from Yorkshire Cancer Research and six other charities, highlighting the potential for PARP Inhibitors to be used in the prevention setting.
People who carry BRCA1 or BRCA2 gene mutations (BRCAm) have a significantly higher risk of developing some types of cancer, including breast, ovarian, prostate and pancreatic cancers.
Applications are invited for proposals which aim to establish:
- If any people with a BRCAm would consider taking PARPi as a preventive measure in place of, or to delay, other current options for risk reduction, such as surgery.
- What information people with BRCAm would require in order to consider taking part in clinical research to understand how to best use PARPi in the prevention setting.
Key information
Amount available: £350,000
Duration: up to 2 years
Funding Round opens: 9 October 2025
Deadline for applications: 12 noon, 18 December 2025
Research Advisory Panel meeting: Wednesday 25 February 2026 - applicants will be invited to present at the meeting
Funding decisions: March 2026
Before applying, please read Information for Applicants 2026 Special PARPi Round.
To apply: visit the Flexi-Grant application portal.
Applicants who are new to Yorkshire Cancer Research will need to register a Flexi-Grant account by clicking the ‘Register’ button.
If you have any questions, please contact research@ycr.org.uk